Qualigen Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-08-13.
Qualigen Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 13, 2025. The filing reports $4.50M sold. Its industry group is Biotechnology. It names Kevin Richardson II (Director), Campbell Becher (Executive Officer, Director), Braeden Lichti (Director) (SEC Form D, August 13, 2025).
Is this your company?
Sell to companies like Qualigen Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Qualigen Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Qualigen Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in August 2025, largest first.
Get an email when Qualigen Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Qualigen Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Qualigen Therapeutics, Inc. →Get the full cited report on Qualigen Therapeutics, Inc.
What the filing shows about Qualigen Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Qualigen Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Qualigen Therapeutics, Inc.'s address as 5857 Owens Avenue, Suite 300, Carlsbad, CA 92008.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Qualigen Therapeutics, Inc. See pricing
Qualigen Therapeutics, Inc. is a registered filer with the SEC (CIK 1460702) and has filed since 2024-11-22. 2 filings are on record, the latest on 2025-08-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Qualigen Therapeutics, Inc.'s Form D of 2025-08-13 names Kevin Richardson II, Campbell Becher, Braeden Lichti and 2 more as its officers, directors or promoters.
Its new offerings report $9.60M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Kevin Richardson II is named as Director on the Form D that Qualigen Therapeutics, Inc. filed with the SEC on 13 August 2025, one of 5 people that filing names.
Campbell Becher is named as Executive Officer and Director on the Form D that Qualigen Therapeutics, Inc. filed with the SEC on 13 August 2025, one of 5 people that filing names.
Braeden Lichti is named as Director on the Form D that Qualigen Therapeutics, Inc. filed with the SEC on 13 August 2025, one of 5 people that filing names.
Robert Lim is named as Director on the Form D that Qualigen Therapeutics, Inc. filed with the SEC on 13 August 2025, one of 5 people that filing names.
Cody Price is named as Director on the Form D that Qualigen Therapeutics, Inc. filed with the SEC on 13 August 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-08-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Qualigen Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Qualigen Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Qualigen Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Qualigen Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Qualigen Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Qualigen Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/qualigen-therapeutics-inc-form-d-25000001